文献速递免疫规划慢病防控与筛查

2012-2016年美国高风险疾病患者流感疫苗有效性研究

Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016.
PubMed 文献 · Vaccine · 2018-11-09

该研究分析了2012-2016年美国流感疫苗有效性网络数据,比较标准剂量灭活疫苗对≥6月龄高风险与非高风险患者实验室确诊流感的有效性。结果显示,高风险患者总体疫苗有效性为41%(95%CI:35-47%),低于非高风险患者的48%(95%CI:43-52%),但疫苗仍提供保护,支持每年接种推荐。

要点

  • 高风险患者流感疫苗有效性为41%,非高风险患者为48%(P交互=0.02)。
  • 儿童中高风险与非高风险患者疫苗有效性相似(51% vs 52%)。
  • 成人中高风险与非高风险患者疫苗有效性相似(38% vs 44%)。

核心结论

  • 流感疫苗为高风险疾病患者提供针对医学就诊流感的保护,水平接近非高风险患者。
  • 分析结果支持对高风险疾病患者每年接种流感疫苗的推荐。

研究设计与样本

  • 研究采用检测阴性设计,分析2012-2016年美国流感疫苗有效性网络数据。
  • 纳入≥6月龄急性呼吸道疾病患者,通过RT-PCR检测流感,从医疗记录获取高风险状况和接种状态。
  • 共纳入25369例患者,其中9643例(38%)有高风险状况,2213例(23%)流感检测阳性。

主要发现

  • 所有年龄中,高风险患者针对任何流感的疫苗有效性为41%(95%CI:35-47%),非高风险患者为48%(95%CI:43-52%),交互作用P=0.02。
  • 儿童(<18岁)中,高风险与非高风险患者疫苗有效性分别为51%(95%CI:39-61%)和52%(95%CI:39-61%),交互作用P=0.54。
  • 成人(≥18岁)中,高风险与非高风险患者疫苗有效性分别为38%(95%CI:30-45%)和44%(95%CI:38-50%),交互作用P=0.21。
  • 儿童和成人中,针对甲型H3N2、甲型H1N1pdm09和乙型流感病毒感染的疫苗有效性在高风险与非高风险患者间相似。

临床怎么用

  • 应继续推荐高风险疾病患者每年接种流感疫苗,因其仍能提供针对医学就诊流感的保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Annual influenza vaccination has been recommended for persons with high-risk conditions since the 1960s. However, few estimates of influenza vaccine effectiveness (VE) for persons with high-risk conditions are available. METHODS: Data from the U.S. Influenza Vaccine Effectiveness Network from 2012 to 2016 were analyzed to compare VE of standard-dose inactivated vaccines against medically-attended influenza among patients aged ≥6 months with and without high-risk medical conditions. Patients with acute respiratory illness were tested for influenza by RT-PCR. Presence of high-risk conditions and vaccination status were obtained from medical records. VE by influenza virus type/subtype and age group was calculated for patients with and without high-risk conditions using the test-negative design. Interaction terms were used to test for differences in VE by high-risk conditions. RESULTS: Overall, 9643 (38%) of 25,369 patients enrolled during four influenza seasons had high-risk conditions; 2213 (23%) tested positive for influenza infection. For all ages, VE against any influenza was lower among patients with high-risk conditions (41%, 95% CI: 35-47%) than those without (48%, 95% CI: 43-52%; P-for-interaction = 0.02). For children aged <18 years, VE against any influenza was 51% (95% CI: 39-61%) and 52% (95% CI: 39-61%) among those with and without high-risk conditions, respectively (P-for-interaction = 0.54). For adults aged ≥18 years, VE against any influenza was 38% (95% CI: 30-45%) and 44% (95% CI: 38-50%) among those with and without high-risk conditions, respectively (P-for-interaction = 0.21). For both children aged <18 and adults aged ≥18 years, VEs against illness related to influenza A(H3N2), A(H1N1)pdm09, and influenza B virus infection were similar among those with and without high-risk conditions. CONCLUSIONS: Influenza vaccination provided protection against medically-attended influenza among patients with high-risk conditions, at levels approaching those observed among patients without high-risk conditions. Results from our analysis support recommendations of annual vaccination for patients with high-risk conditions.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Shang M, Chung JR, Jackson ML, et al. Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016. Vaccine. 2018. PMID: 30420119. doi:10.1016/j.vaccine.2018.10.093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。